Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

RSS icon
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Agent Drug-Coated Balloon (DCB) for the treatment of coronary in-stent restenosis (ISR) in patients with coronary artery disease.

FDA approves Boston Scientific’s new drug-coated balloon for coronary in-stent restenosis

Interventional cardiologists have been anticipating this news for quite some time. The device, the first of its kind, provides an alternative treatment option to repeat PCI or cardiac surgery for patients with coronary ISR.

healthcare business deal

Cardiologists partner with imaging AI specialists to improve care for high-risk heart patients

The new collaboration is designed to ensure patients who may face an increased risk of heart disease receive the follow-up care they need.

Image of the A-FLUX Reducer System for chest pain by VahatiCor

Cardiologists make history, treat world’s first patient with new interventional device for chest pain

The self-expandable device was designed to treat “no-option” chest pain patients who see no long-term benefits from other interventions. 

Regularly eating avocados is associated with a reduced risk of cardiovascular disease, according to a new study.

Top 5 diets for heart health: Expert panel puts Mediterranean, DASH at the top

The Ornish diet, a plant-based option developed to help prevent heart disease, also made the final ranking. 

artificial intelligence AI heart cardiology

Cleerly’s AI software for noninvasive FFR estimates receives a Category 1 CPT code

The company officially launched its Cleerly ISCHEMIA software for delivering noninvasive evaluations of CCTA exams in early 2024. This update provides a closer look at the software from a billing perspective. 

Insurance plans still denying more claims for PCSK9 inhibitors than other cardiovascular drugs

Despite an expanded indication from the FDA and lower prices, patient access to these cholesterol-lowering medications remains a significant issue.

HeartFlow’s AI-powered CAD offering receives new CPT code with improved reimbursement rate

For this update to be finalized, the American Medical Association had to determine FFRCT Analysis met certain requirements in terms of its overall impact on patient care. John Farquhar, CEO of HeartFlow, described the news as "a win for everyone involved, most notably patients." 

heart patient

Heart specialists push for change due to rising number of CVD deaths

"It’s clear to me that urgent intervention is long overdue," one cardiologist said in a statement. 

Displaying 81 - 88 of 667

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.